Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Tg Therapeutics (TGTX) Gross Margin (2021 - 2025)

Tg Therapeutics has reported Gross Margin over the past 5 years, most recently at 80.19% for Q4 2025.

  • Quarterly results put Gross Margin at 80.19% for Q4 2025, down 557.0% from a year ago — trailing twelve months through Dec 2025 was 83.66% (down 464.0% YoY), and the annual figure for FY2025 was 83.66%, down 464.0%.
  • Gross Margin for Q4 2025 was 80.19% at Tg Therapeutics, down from 82.63% in the prior quarter.
  • Over the last five years, Gross Margin for TGTX hit a ceiling of 97.88% in Q3 2023 and a floor of 80.19% in Q4 2025.
  • Median Gross Margin over the past 5 years was 88.11% (2023), compared with a mean of 88.34%.
  • Biggest five-year swings in Gross Margin: tumbled -1411bps in 2023 and later skyrocketed 363bps in 2024.
  • Tg Therapeutics' Gross Margin stood at 82.47% in 2021, then grew by 17bps to 96.25% in 2022, then dropped by -15bps to 82.14% in 2023, then increased by 4bps to 85.77% in 2024, then decreased by -6bps to 80.19% in 2025.
  • The last three reported values for Gross Margin were 80.19% (Q4 2025), 82.63% (Q3 2025), and 86.58% (Q2 2025) per Business Quant data.